CAJ | 학술논문

目的：探讨JNK信号通路抑制剂(SP600125)体内长期实验的应用方法。方法将40只新西兰兔随机分为八组：空白对照组、模型对照组、JNK高剂量组、JNK低剂量组、JNK空白组、DMSO模型组、DMSO空白组、阳性对照组。自实验第一天开始各组给予相应处理，连续4周。4周末检测实验兔心肌组织JNK总蛋白及蛋白磷酸化和基因表达水平。结果经阿霉素干预后，各组实验组心肌P-JNK表达均不同程度上调，其中以模型对照组、DMSO模型组上调最为明显(P<0.05)。JNK低、高剂量组和阳性对照组心肌P-JNK表达水平上调较模型对照组缓慢(P<0.05)，其中以JNK高剂组心肌P-JNK水平上调最为缓慢(P<0.05)。各实验组间JNK总蛋白、JNK mRNA表达差异无统计学意义(P>0.05)。结论连续4周小剂量皮下注射JNK信号通路抑制剂可以显著下调p-JNK的表达，该方法能够为体内长期实验研究提供思路。
목적：탐토JNK신호통로억제제(SP600125)체내장기실험적응용방법。방법장40지신서란토수궤분위팔조：공백대조조、모형대조조、JNK고제량조、JNK저제량조、JNK공백조、DMSO모형조、DMSO공백조、양성대조조。자실험제일천개시각조급여상응처리，련속4주。4주말검측실험토심기조직JNK총단백급단백린산화화기인표체수평。결과경아매소간예후，각조실험조심기P-JNK표체균불동정도상조，기중이모형대조조、DMSO모형조상조최위명현(P<0.05)。JNK저、고제량조화양성대조조심기P-JNK표체수평상조교모형대조조완만(P<0.05)，기중이JNK고제조심기P-JNK수평상조최위완만(P<0.05)。각실험조간JNK총단백、JNK mRNA표체차이무통계학의의(P>0.05)。결론련속4주소제량피하주사JNK신호통로억제제가이현저하조p-JNK적표체，해방법능구위체내장기실험연구제공사로。
Objective To explore the method for the long-term in vivo application of JNK signaling pathway in-hibitor (SP600125). Methods Forty New Zealand rabbits were randomly divided into 8 groups: blank control group, model control group, high-dose JNK group, low-dose JNK group, JNK blank group, DMSO model group, DMSO blank group, positive control group. All the experimental groups received the corresponding treatment for 4 weeks. After 4 weeks, the myocardial tissues of experimental rabbits were separated under anesthesia, and JNK total protein and p-JNK protein were measured bn Western blot. JNK mRNA expression was measured by RT-PCR. Results After intervention of ADR, myocardial P-JNK expression in each experimental group increased to different degrees, and the increases in the model control group, DMSO model group were the most significant (P<0.05). Compared with model control group, the increases in myocardial P-JNK expression in low-dose JNK group, high-dose JNK group and positive con-trol group were less significant (P<0.05), and the myocardial P-JNK levels in high-dose JNK group increased most slowly (P<0.05). The total protein of JNK, JNK mRNA expression of the experimental groups showed no significant difference (P>0.05). Conclusion Low-dose subcutaneous injection of JNK signaling pathway inhibitor for four weeks can significantly lower the expression of p-JNK.